Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Basic Science, biomarkers, new diagnostics and translational research

1045 - A high throughput compound screen identifies potential combinations to overcome resistance to Cdk2 inhibitors in Cyclin E1 amplified high grade serous ovarian cancer


21 Dec 2015


Basic Science, biomarkers, new diagnostics and translational research


George Au-Yeung


Annals of Oncology (2015) 26 (suppl_9): 1-7. 10.1093/annonc/mdv517


G. Au-Yeung1, F. Lang1, C. Mitchell1, K. Jarman2, K. Lackovic2, C. Cullinane3, L. Mileshkin4, D. Rischin4, D. Etemadmoghadam1, D. Bowtell1

Author affiliations

  • 1 Cancer Genetics And Genomics, Peter MacCallum Cancer Center, 3002 - Melbourne/AU
  • 2 Systems Biology And Personalised Medicine Division, Walter and Eliza Hall Institute WEHI, Parkville/AU
  • 3 Cancer Therapeutics, Peter MacCallum Cancer Center, Melbourne/AU
  • 4 Division Of Cancer Medicine, Peter MacCallum Cancer Center, 3002 - Melbourne/AU

Abstract 1045


High grade serous ovarian cancer (HGSOC) is the most common histological subtype of ovarian cancer, accounting for approximately 70-80% of deaths. Cyclin E1 (CCNE1) amplification is detected in up to 15% of HGSOC, and has been shown to be associated with primary treatment resistance and poor outcome. Cyclin E1 is a cell cycle regulator that partners with cyclin-dependent kinases (CDK) to signal within cells, particularly Cdk2. We aim to identify strategies to target CCNE1 amplification in HGSOC using preclinical studies, and investigate potential resistance mechanisms to these targeted agents.


We have previously demonstrated that ovarian cancer cells with CCNE1 amplification are specifically sensitive to Cdk2 inhibitors. In addition, we generated ovarian cancer cell lines that are resistant to dinaciclib, a potent Cdk2 inhibitor in advanced clinical development. In order to investigate potential drug combinations that would overcome resistance to Cdk2 inhibitors, we performed a high throughput compound screen (HTCS) of over 4,000 drugs in combination with dinaciclib. Hits were then assessed using the Chou-Talalay isobologram method to characterise the interaction for each individual drug combination. Synergistic drug combinations were then validated in drug cytotoxicity assays across additional resistant ovarian cancer cell lines to identify common resistance mechanisms.


The HTCS identified multiple compounds that were synergistic in combination with dinaciclib in Cdk2 inhibitor resistant cells. Two BH3 mimetics (pro-apoptotic compounds), ABT-737 and ABT-263 were selectively synergistic with dinaciclib in resistant cell lines. By contrast, ABT-199, a selective Bcl-2 inhibitor, was not synergistic with dinaciclib. Our findings indicate that multiple proteins in the pro-apoptotic pathway must be targeted to overcome resistance to Cdk2 inhibitors.


Results from a HTCS indicate that targeting multiple components of the apoptotic pathway using BH3 mimetics may overcome resistance to Cdk2 inhibitors in CCNE1 amplified HGSOC. Ongoing studies will provide further insights into the underlying biology of drug resistance.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings